American Century Companies Inc. acquired a new stake in shares of Glaukos Co. (NYSE:GKOS) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 5,556 shares of the medical instruments supplier’s stock, valued at approximately $471,000.
A number of other hedge funds and other institutional investors have also recently modified their holdings of GKOS. Altshuler Shaham Ltd acquired a new position in Glaukos during the first quarter valued at approximately $38,000. Eaton Vance Management acquired a new position in Glaukos during the first quarter valued at approximately $40,000. Benjamin F. Edwards & Company Inc. acquired a new position in Glaukos during the first quarter valued at approximately $50,000. Marshall Wace North America L.P. bought a new position in Glaukos in the first quarter valued at approximately $55,000. Finally, Fifth Third Bancorp lifted its stake in Glaukos by 566.7% in the first quarter. Fifth Third Bancorp now owns 800 shares of the medical instruments supplier’s stock valued at $67,000 after buying an additional 680 shares in the last quarter.
A number of research analysts have weighed in on the stock. TheStreet lowered shares of Glaukos from a “c-” rating to a “d+” rating in a research note on Wednesday, May 26th. Stephens cut their price target on shares of Glaukos from $70.00 to $60.00 and set an “equal weight” rating on the stock in a research note on Friday, August 6th. Citigroup cut their price target on shares of Glaukos from $94.00 to $52.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 28th. Wells Fargo & Company lowered shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $41.00 price objective on the stock. in a research report on Tuesday, July 20th. Finally, Piper Sandler cut their price objective on shares of Glaukos from $80.00 to $45.00 and set a “neutral” rating on the stock in a research report on Friday, August 6th. Two research analysts have rated the stock with a sell rating and seven have assigned a hold rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $59.00.
Glaukos (NYSE:GKOS) last released its quarterly earnings data on Thursday, August 5th. The medical instruments supplier reported ($0.11) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.13. Glaukos had a negative net margin of 21.24% and a negative return on equity of 3.13%. The firm had revenue of $78.09 million for the quarter, compared to the consensus estimate of $71.00 million. On average, research analysts anticipate that Glaukos Co. will post -0.85 EPS for the current fiscal year.
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B.
Read More: Find a Trading Strategy That Works
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Co. (NYSE:GKOS).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.